Allan Safferman M.D.

Dr. Safferman is Vice President and Unit Head (oncology, rare disease, internal medicine, and global brands products) Safety Surveillance and Risk Management, Worldwide Safety at Pfizer. Prior to joining Pfizer he was Executive Director and Therapeutic Area Head for Oncology Medical Safety Assessment, Global Pharmacovigilance and Epidemiology at Bristol Myers. Before joining Bristol Myers he was at Pfizer where he held positions in clinical research and drug safety. Prior to joining Industry he was a Research Psychiatrist at Hillside Hospital conducting research with clozapine and other antipsychotic agents for the treatment of patients with schizophrenia. Dr. Safferman completed his internship and residency in Psychiatry at Hillside Hospital, a division of Long Island Jewish Medical Center in Glen Oaks, NY after receiving his Medical Degree at Rosalind Franklin University of Medicine and Sciences in North Chicago, Illinois. He received a BS degree in Biology and Economics at State University of New York at Stony Brook.